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Abstract 
Purpose: Platinum resistant ovarian cancer (PROC) constitutes a therapeutic dilemma 
with limited efficacy from traditional cytotoxic agents. Based on prior data suggesting 
that scheduling alterations of platinum would increase activity, the aim of the present 
study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel 
biomodulator shown to have chemoresistance reversing potential, when combined with 
weekly AUC2-carboplatin in PROC-patients. 
Patients and Methods: A multicenter randomized double-blind placebo controlled 
phase-III-study was conducted to compare oral PXD plus AUC2-carboplatin (group 1) 
versus placebo plus AUC2-carboplatin (group 2) weekly in PROC-patients. The primary 
end point was progression-free-survival (PFS). Secondary objectives included overall 
survival (OS), response rates, duration of response and quality of life.  
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Results: A total of 142 patients were randomized. The groups were well balanced in 
terms of important baseline characteristics. The median PFS for group 1 was 15.4 weeks 
(95%CI=11.1-21.0) versus 20.1 weeks for group 2 (95%CI=13.1-33.4); p=0.3. The 
objective response rate and median survival in group 1 versus group 2 was 0% versus 1% 
and 38.3 weeks (95%CI=32.0-45.3) versus 45.7 weeks (95%CI=35.6-58.0), respectively. 
PXD appeared to be well tolerated. The main reason for dose modification in both groups 
was hematologic toxicity.  
Discussion: Orally delivered PXD showed no evidence of clinical activity, when 
combined with weekly AUC2-carboplatin in PROC. In addition, weekly AUC2-
carboplatin appeared to be inactive in a homogenously defined population of PROC. This 
has implications for the design of future studies.    
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in females in 
the western countries and the most lethal gynecological malignancy.1-3 While platinum-
based chemotherapy results in high response rates ranging from 50-80%,4 70% of 
patients will relapse and eventually develop PROC with a corresponding adverse 
prognosis associated with this transition.5-8  
The treatment of PROC utilizes non-platinum agents such as gemcitabine, pegylated 
liposomal liposomal doxorubicin, paclitaxel, vinorelbine and topotecan, however the 
development of resistance to platinum is associated with cross resistance to other drugs 7 
resulting in very low response rates of 3-16%.8 This acquired chemo-resistance represents 
one of the major hurdles to effective treatment of ovarian cancer and creates therapeutic 
dilemmas.  
Reversal of chemotherapy resistance has been an attractive strategy in principle and much 
effort has been expended in trying to understand mechanisms of chemotherapy 
resistance.24 Dose dense application of paclitaxel and cisplatin in phase II and 
randomized phase III trials showed a clear increase in overall response rates in relapsed 
PROC.19-20,23,37  
Phenoxodiol (PXD) is a sterically-modified version of the naturally-occurring plant 
isoflavone, genistein. Pre-clinical studies suggest that exposure of human cancer cells to 
PXD results in up regulation of pro-apoptotic ceramide lipid levels with a concomitant 
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reduction in sphingosine-1-phosphate leading to AKT inhibition.9-12 Two well described 
biological effects of PXD are mitotic arrest of tumour cells in the G1 phase of the cell 
cycle as a result of p53-independent upregulation of p21 Waf1/CIP1 and induction of 
apoptosis through inhibition of phosphorylation of the anti-apoptotic proteins, X-linked 
inhibitor of apoptosis (XIAP) and FLIPshort.11  
PXD has shown both additive and synergistic interactions with chemotherapies including 
cisplatin, carboplatin, gemcitabine, paclitaxel, docetaxel and topotecan in a wide range of 
human cancer cells, including human ovarian cancer cells.10,12-15 In a phase II study of 
intravenous PXD combined with either cisplatin or paclitaxel in PROC, stable disease 
rates of more than 55% and overall best response rates as high as 19% could be achieved 
with good tolerance.16  No phase II efficacy studies were conducted with oral phenoxodiol 
prior to the initiation of OVATURE (Ovarian Tumor Response), however, phase I/II 
safety and pharmacokinetic studies with oral phenoxodiol suggested that the drug was 
immediately conjugated (glucuronidated) to an inactive metabolite and animal models 
demonstrated that this conjugation and inactivation was reversed within tumors, 
providing a tumor targeting strategy. This was the primary rationale to proceed with 
OVATURE (Clinicaltrials.gov identifier NCT00382811).11,13,16-18 
Based on the promising phase II results in PROC, this trial was designed to confirm a 
clinically important interaction of PXD and carboplatin in this patient population.  
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PATIENTS and METHODS 
Patients 
PROC-patients with histologically-confirmed non-mucinous ovarian, fallopian tube, or 
primary peritoneal carcinoma of epithelial origin were eligible for the study if they 
fulfilled all of the following criteria: patients must have received at least one line of 
platinum based chemotherapy (cisplatin or carboplatin) for recurrence having responded 
to first line therapy previously; platinum resistant recurrence was defined as RECIST 
measurable disease relapse within 6 months of completing a second or subsequent course 
of platinum therapy at the time of enrollment, taken from the last day of platinum 
therapy. Measurable disease had to be ≥10 mm when measured by spiral CT and ≥20 mm 
when measured by conventional CT. Patients had an estimated survival of at least 3 
months; a Karnofsky-Performance-Score (KPS)≥60; and biochemical/hematological 
function within the normal range.  
The study was conducted in accordance with Good Clinical Practice (GCP) according to 
ICH guideline CPMP/ICH/135/95 and the Declaration of Helsinki (V11 Oct,2000) with 
notes of Clarification in 2002 (Washington) and 2004 (Tokyo). 
 
Study Design 
The primary objective of this study was to compare the effect of a treatment regime of (1) 
daily oral phenoxodiol in combination with weekly carboplatin, versus (2) daily oral 
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placebo in combination with weekly carboplatin on the progression free survival (PFS) in 
patients with PROC. Secondary objectives included comparisons of overall response 
rates (ORR) and duration of response (DOR), overall survival (OS), and quality of life 
(QoL).  We also evaluated two additional endpoints: a) time to dose reduction due to 
toxicity in order to assess a postulated benefit of phenoxodiol to improve the tolerance to 
carboplatin and b) disease control rate, defined as any response achieved other than 
progressive disease (i.e., complete response, partial response, or stable disease). 
Weekly carboplatin can be delivered as a single agent at an AUC not exceeding 2, 
although when given with weekly paclitaxel, the thromboprotective effect of paclitaxel 
allows an increase in weekly carboplatin. In this trial we were able to dissect the effects 
of schedule from those of dose in recurrent PROC, with carboplatin being given weekly 
at a non dose-dense AUC2, the maximum tolerated single agent dose. The patients 
groups and regimes are described in figure 1. 
 
Treatment and Follow-up Procedures 
Patients were randomized, 1:1, to either (1) PXD + carboplatin or (2) Placebo + 
carboplatin. Both PXD and the placebo were taken daily every 8-hours.  
Carboplatin was given weekly over 1 hour at a dosage of AUC2. Although not validated 
for single agent platinum compounds, a change in regime from 3-weekly to weekly had 
been shown with taxanes19,20 and also with the combination of carboplatin and taxol34,48 
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demonstrating tumor response in patients whose tumors have become resistant to a 3-
weekly regime. Carboplatin dosing was based on the Calvert and, Cockroft-Gault 
formulae. 
Phenoxodiol: PXD was administered orally, 400mg (2x200 mg capsules) every 8 hours 
continuously, unless body weight was >100kg where a 50% increase to 600mg (3x200 
mg capsules) was used. PXD was taken on an empty stomach at least 30 min prior to 
eating. No toxicities or intolerances are known to be associated with the use of the oral 
dosage form of PXD, and therefore no precautions or preventative therapies were 
contemplated. 
A treatment cycle was defined as 28 days (4 weeks).  Treatment with both carboplatin 
and PXD or placebo was to be continued until disease progression, dose-limiting toxicity, 
or patient withdrawal.  Dose adjustments or interruptions of carboplatin were undertaken 
based on toxicity using standard criteria for both drugs. 
Patients were evaluated weekly for evidence of toxicity, including hematology and 
routine chemistry laboratory studies. Efficacy assessments, specifically computed 
tomography (CT) scanning, was performed every 8 weeks (2 cycles). In addition, CA125 
levels were measured every 2 weeks. QoL instruments (FACT-O and FACT-BRM) were 
administered every 8 weeks (2 cycles).  
 
Endpoints and Sample Size 
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Clinical response and progression were assessed according to the RECIST criteria22 and 
based on the assessment determined by an independent Tumor Response Evaluation 
Committee (TREC) rather than the investigator. In addition, CA-125 response and 
progression was assessed according to the Rustin criteria. PFS (the primary endpoint) 
was measured from the day of randomization to the day of documented disease 
progression or death while OS was measured from the day of randomization to death. 
Stable disease was defined as any response between PR and DP. 
Toxicity was assessed according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 3 (CTCAE v3). 
 
 
Statistical Analysis 
The study was originally designed to detect an improvement in median PFS from 
approximately 5 months in the control group to approximately 8 months in the 
experimental group, corresponding to a PFS hazard ratio of 0.625. Based on a projected 
recruitment duration of 36 months a sample size of 340 patients was planned. A single 
interim analysis was pre-specified at ~50% of the planned PFS events (~95/190), utilizing 
O’Brien-Fleming stopping boundaries at an alpha level of 0.005. The final analysis was 
planned at a two-sided alpha of 0.048. All efficacy analyses were conducted on all 
randomized patients (intention-to-treat population) while all toxicity analyses were 
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conducted on the safety population defined as all randomized patients who received at 
least one dose of protocol defined therapy. Patients who discontinued protocol defined 
therapy prior to disease progression or death were censored at 1) the last date of tumor 
evaluation for the PFS analysis and 2) the last date of known contact for the OS analysis. 
Based on an observed recruitment velocity that was far below what was originally 
projected, an amended statistical analysis plan was developed. Recruitment was formally 
stopped on 14 April 2009. The amended statistical analysis plan specified removing the 
original planned interim analysis and replacing it with a new interim PFS analysis that 
was time specified (data cut off: 01 June 2009). It was projected that approximately 70% 
of the enrolled patients would have experienced a PFS event at this time point (~98 
patients) and the alpha level for this new analysis was kept at 0.005, as per the original 
interim analysis plan. A revised final analysis was planned when all enrolled patients had 
either died, completed 18 months of follow-up, or had been lost to follow-up.  
 
RESULTS 
Patients 
Between November 2006 and March 2009, 142 patients were randomized at 49 study 
sites in the OVATURE study; 72 patients to Placebo+Carboplatin and 70 to 
PXD+Carboplatin (Fig 1). At the time of the interim PFS analysis, 110 patients had 
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progressed or died without evidence of progression and 32 were censored (19 in the 
control group and 13 in the PDX group). At the time of the final OS analysis 118 patients 
had died and 24 were censored (13 in the control group and 11 in the PDX group). The 
median age was 57.5 years (range: 39-78)  in the PXD/Carboplatin group and 59.0 
years (range: 37-82) in the Placebo/Carboplatin group.  Both arms were well balanced 
regarding important baseline characteristics, stratification factors, duration of study 
treatments, number of treatment cycles and other patient characteristics (Table 1). All 
patients in the study reported at least one comorbidity mainly in terms of gastrointestinal-
, nervous system- or respiratory disorders.  No significant differences in the comorbidities 
were noted between the two patients arms.  
Withdrawals are summarized by subgroup in table 2. There were similar numbers of 
patients in each treatment group attending each visit and having evaluable tumor 
responses. The duration of study treatments and number of treatment cycles were similar 
between the two treatment groups and there were no obvious differences seen within any 
of the subgroups. Prior treatment and platinum-free interval were well balanced between 
the arms and are presented by cohort and overall in Table 3.  All patients had received 
prior carboplatin or cisplatin.   
 
Efficacy  
RECIST outcomes 
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PFS, the primary study endpoint, was similar in the two groups, 20.1 weeks in the 
placebo group versus 15.5 weeks in the PDX group (HR=1.22, 95%CI 0.84-1.22, 
p=0.30). No differences between the treatment groups were noted for the secondary 
efficacy endpoints. OS was 45.7 weeks in the placebo group versus 38.3 weeks in the 
PDX group (HR=1.20, 95%CI 0.83-1.73, p=0.33. Exploratory analyses across a variety 
of pre-specified patient sub-groups did not identify a population that appeared to derive 
clinical benefit.  The median time to progression for the PXD group was 15.4 weeks 
(95%CI = 11.1-21.0) and was 20.1 weeks for the placebo group (95%CI = 13.1-33.4).  
The median OS was also not statistically significantly different between the two groups 
with 38.3 weeks (95%CI=32.0- 45.3) in the PXD group compared with 45.7 weeks 
(95%CI=35.6-58.0) in the Placebo group (p=0.3).  The hazard ratio was 1.2 (95% 
CI=0.83-1.73). Survival curves for OS and PFS are presented in figures 2 and 3. 
 
Confirmed ORR was 1.4% in the placebo group versus 0% in the PDX group while stable 
disease was 52.8% and 51.4% respectively.  A similar, non significant number of patients 
in each treatment group had stable disease (36 vs. 38; 51.4% vs. 52.8% for PXD and 
Placebo, respectively) in the ITT population. Overall response rates (ITT population) are 
presented in detail in table 4.  
 
CA125 outcomes  
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When evaluating CA125 levels, there was no indication of a treatment effect in response 
as defined by a sustained fall of at least 50% in CA-125 for patients who had a valid 
baseline measure of CA125 in any of the subgroups.  Also there was no indication of a 
treatment effect in progressive disease as defined by two consecutive values at least 7 
days apart ≥2xULN in any of the subgroups. 
 
No differences in quality of life or performance status were noticed between the two 
groups over the course of treatment. 
 
Adverse events 
Table 5 summarizes the dose modification in both arms of the trial. A total of 1362 AEs 
occurred post treatment in the phenoxodiol+carboplatin group and 1374 occurred in the 
placebo+carboplatin group. There were 518 AEs which were deemed possibly, probably 
or definitely related to the phenoxodiol+carboplatin combination and 472 to the 
placebo+carboplatin combination by the investigators.  The majority of adverse events 
were mild (Grade 1) for both groups.  
 
The most common adverse events in both groups were blood, lymphatic system and 
gastrointestinal disorders in terms of neutropenia, thrombocytopenia and diarrhea.   
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There were six serious adverse events which resulted in death and were largely the result 
of progressive disease. No treatment related grade 3 or 4 toxic changes were recorded in 
the liver or kidney function tests. Also no grade 3 or 4 disorders occurred in the 
musculoskeletal and connective tissue, nervous system, respiratory, thoracic and 
mediastinal system or any severe psychiatric deterioration in terms of lethargy or 
depression. Table 6 presents the most relevant treatment related toxicities.  
 
DISCUSSION 
This is a prospective randomized trial evaluating the efficacy of weekly carboplatin in 
combination with the oral sensitizer phenoxodiol in PROC. Even though weekly 
carboplatin had not been previously evaluated in PROC, it was considered justifiable 
based on data for other agents such as paclitaxel and cisplatin (and their combination). 
The development of weekly scheduling of platinum based drugs has a significant history. 
Accelerated weekly cisplatin schedules have demonstrated good efficacy in a variety of 
contexts, particularly as a component of primary chemoradiotherapy in cervical cancer in 
randomized phase III clinical trials with positive survival outcomes; furthermore, 
enhanced response rates of 25-60% especially for combinations with paclitaxel  were 
observed in platinum resistant ovarian cancer.23,34-40,48-51  
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The impact of non-dose-dense -but nevertheless maximal tolerated dose- scheduling 
change to weekly single agent carboplatin AUC2 had not been previously evaluated in 
PROC, but from first principles might have been expected to have some activity. 
In parallel, the understanding of mechanisms underlying clinical platinum resistance has 
expanded utilizing clinically appropriate translational models of intrapatient matched 
clinically sensitive and resistant cancer cell lines41-43,47 and molecules such as VEGF, 
BRCA2, HDAC4, STAT3, AKT, and DNA-PK have become implicated in acquired 
platinum resistance. 
This report summarizes the first clinical phase III trial, to our knowledge, to study the 
impact of fractionating the schedule of carboplatin in a single agent AUC2 weekly 
regime as a chemotherapeutic backbone in order to evaluate the impact of phenoxodiol, 
an chemo sensitizer with multiple postulated effects: pan protein tyrosine kinase 
inhibition, AKT inhibition and anti-angiogenesis in patients with PROC. Despite 
promising preclinical and early clinical results of PXD against epithelial cancers27-33, and 
also promising data suggesting some impact from weekly-scheduled cisplatin and 
carboplatin delivering enhanced activity in PROC 19-21,23-25, this study could not 
demonstrate that phenoxodiol improved the outcome of patients with PROC receiving 
weekly AUC2 carboplatin. No significant difference was seen between the two arms of 
the study with respect to median PFS or OS, with a highly homogenous population of 
patients with acquired (not refractory) platinum resistance. The study was therefore 
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terminated appropriately at first interim analysis after enrollment of 142 out of 340 
planned patients due to the absence of any difference between the arms. 
Whilst it is understandable that a novel agent such as phenoxodiol could have shown no 
impact on the primary endpoint, the data within this study relating to the non-activity of 
weekly scheduled carboplatin AUC2 in PROC are striking and important since they have 
significant implications for the directions of clinical research in both PROC and also for 
the strategy surrounding scheduling and dose dense approaches in front line therapy in 
ovarian cancer. 
Sharma et.al. reported their experience with dose dense carboplatin AUC3 and 70mg/m2 
paclitaxel weekly and demonstrated a 60%-RECIST response rate in platinum 
resistant/refractory ovarian cancer with an 8 month median PFS.34 The authors noted the 
protective effect of paclitaxel against carboplatin-induced thrombocytopenia, which 
enabled an activity enhancement of carboplatin through dose increase without the 
associated toxicity.24,44 Other investigators also confirmed that the weekly combination of 
carboplatin and paclitaxel in platinum refractory disease could achieve response rates 
ranging from 25% to 60%.45,4648-51 
Although no pharmacokinetic data or intra-tumoral drug levels were obtained in 
OVATURE, the lack of discernible adverse events or anti-tumor activity raise suspicion 
that oral administration of phenoxodiol may have been less effective than the clearly 
active intravenous administration of the same agent. Regardless, these data do not support 
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further clinical development of oral phenoxodiol in human cancer and strongly indicate 
that weekly AUC2 carboplatin should not be considered for use in PROC either on its 
own or as a chemotherapeutic backbone for studies targeting platinum resistance reversal. 
The high priority area of understanding and applying therapeutic strategies that target the 
mechanisms of acquired platinum resistance in the context of the use of platinum based 
chemotherapy in PROC is an undiminished area of unmet need and is complementary 
and synergistic with other efforts to do the same with non-platinum chemotherapies. 
Future research should focus on translating our growing understanding of molecular 
mechanisms underlying platinum resistance and the identification of tumors that may be 
responsive to these approaches by better predictive biomarker signatures that may 
indicate those who would benefit from the reintroduction of platinum in combination 
with a molecular agent inhibition-targeting specific pathways that create platinum 
resistance. 
In conclusion, this phase III study of weekly AUC2 carboplatin and placebo versus 
carboplatin plus PXD failed to demonstrate activity or survival benefit through an 
approach of weekly carboplatin scheduling and addition of PXD in a molecularly 
unselected but clinically homogenous population of patients with acquired platinum 
resistant ovarian cancer. Results of this study do not negate the strategy to molecularly 
target platinum resistance in the context of a platinum based chemotherapy backbone in 
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PROC but at the same time do not support future trials that would propose a fractionated 
carboplatin backbone to test reversal of PROC using molecularly targeted agents. 
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Tables: 
Table 1: Demographic, Clinical and Tumor Related Characteristics of 142 patients with 
platinum-resistant ovarian cancer relapse.  
 
Parameter  PXD + carbo 
(n=70) 
Placebo + Carbo 
(n=72) 
Age (years) Median (range) 57.5 (39-78) 59.0 (37-82) 
Race n(%) Caucasian 59 (41.5%) 62 (43.7%) 
 Asian 4 (2.8%) 4 (2.8%) 
 African American 3 (2.1%) 4 (2.8%) 
 Hispanic 2 (1.4%) 0 
 Other 2 (1.4%) 2 (1.4%) 
Performance 
status 
0/1 70% 
 
72% 
 
Primary site of 
malignancy 
Ovary 
Fallopian tube 
Peritoneum 
60 (85.7%) 
1 (1.4%) 
9 (12.9%) 
64 (88.9%) 
2 (2.8%) 
6 (8.3%) 
Histology Serous 
Endometroid 
Clear cell 
Other 
57 (81.4%) 
7 (10%) 
0 
6 (8.6%) 
53 (73.6%) 
6 (8.3%) 
5 (6.9%) 
8 (11%) 
Grade 1 
2 
3 
4 
unknown 
1 (1.4%) 
11 (5.7%) 
44 (62.9%) 
3 (4.3%) 
11 (15.7%) 
2 (2.8%) 
10 (13.9%) 
50 (69.4%) 
1 (1.4%) 
9 (12.5%) 
Stage I 
II 
IIIa-IIIb 
IIIc 
IV 
unknown 
5 (7.2%) 
3 (4.3%) 
7 (10%) 
38 (54.3%) 
16 (22.9%) 
1 (1.4%) 
4 (5.6%) 
2 (2.8%) 
4 (5.6%) 
50 (69.4%) 
10 (13.9%) 
2 (2.8%) 
Number of 
Prior Platinum 
Treatments 
(per Patient) 
1 
2 
3 
>3 
None reported 
3 (  4.3%) 
29 ( 41.4%) 
21 (20%) 
16 (22.9%) 
1 (1.4%) 
 2 (2.8%) 
32 (44.4%) 
14 (19.4%) 
21 (29.2%) 
3 (4.2%) 
Platinum-Free 
Interval 
Median (range) 3.5 (0-37) 2.6 (0-89) 
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(months) 
 
 
 
Table 2: Study Completion and Withdrawal (Safety/ITT population) in patients with 
platinum resistant ovarian cancer relapse treated with either carboplatin alone or 
carboplatin plus phenoxodiol. 
 
 PXD + carbo (n=70) Placebo + carbo (n=72) 
Study completed   
Yes 70 (100%) 72 (100%) 
No 0 (0%) 0 (0%) 
Withdrawal reason   
Disease Progression                                              33 (47.1%) 33 (45.8%) 
Confirmed Complete Response[a]                                    0 ( 0.0%) 0 ( 0.0%) 
Unacceptable Toxicity                                             7 (10.0%) 16 (22.2%) 
Investigator Decision    15 (21.4%) 11 (15.3%) 
Patient's Request 9 (12.9%) 4 ( 5.6%) 
Sponsor Decision                                                  1 ( 1.4%) 1 ( 1.4%) 
Other                                                             5 ( 7.1%) 7 ( 9.7%) 
Missing                                                           0 ( 0.0%) 0 ( 0.0%) 
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Table 3: Prior Treatment of Disease by Dose Cohort (Safety/ITT Population) 
________________________________________________________________________
________ 
                                           PXD + Carboplatin            Placebo + Carboplatin                                   
                                                  (N=70)        (N=72)                                       
________________________________________________________________________
________                                                                                                     
Platinum-Free Interval (months) [b]                                                                                                                    
   N                                                               69                               69                                                 
   Mean                                                         4.7                             4.2                                               
   Standard Deviation                                   6.79                           10.48                                              
   Median                                                      3.5                             2.6                                               
   Minimum-Maximum                                0 - 37                            0 - 89                                           
_________________________________________________________________ 
[a] Defined as treatment with either carboplatin or cisplatin.                                                                                         
[b] Defined as day of enrollment minus date of last day of most recent platinum therapy divided by 30.44 
(365.25/12).                                  
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Table 4: Overall response rates (ITT population) in patients with platinum resistant 
ovarian cancer relapse treated with either carboplatin alone or carboplatin plus 
phenoxodiol. 
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Table 5: Reasons for Dose Modifications (Safety Population) 
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                  PXD + Carboplatin         Placebo + 
Carboplatin                      
                                                                                              (N=66)                          (N=71)                        
________________________________________________________________________________   
Total Number of PXD Dose Modifications [a]                       100                           61                                                                                                                                   
Reason for PXD Dose Modification                                                                                                                       
    Hematologic Toxicity                                                        44 (44.0%)                 31 (50.8%)                                 
    Non-Hematologic Toxicity                                                14 (14.0%)                   8 (13.1%)                                 
    Weight > 100kg                                                                  0 (0.0%)                     0 (0.0%)                                 
    Other                                                                                33 (33.0%)                 22 (36.1%)                                 
    Reason not stated in Data/CRF                                            9 (9.0%)                     0 (0.0%)                                                                                                                                                   
Total Number of Carboplatin Dose Modifications [a]                 224                             198                                                                                                                                                                                 
Reason for Carboplatin Dose Modification                                                                                                               
    Hematologic Toxicity                                                          81 (36.2%)                59 (29.8%)                                 
    Non-Hematologic Toxicity                                                  13 (5.8%)                  13 (6.6%)                                 
    Other                                                                                  52 (23.2%)                41 (20.7%)                                 
    Reason not stated in Data/CRF                                          78 (34.8%)                   85 (42.9%)                                
________________________________________________________________________
______ 
[a] Dose modifications include dose delays and dose reductions.                                                                                        
The denominators are based on the total number of dose modifications    
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Table 6:  Adverse Events Leading to Dose Reduction or Temporary Dose Withdrawal by 
System Organ Class and Preferred Term - (Safety Population) All Grades and > Grade 3 
Adverse Events by Group 
 
                   Maximum CTC Grading 
 ALL Grades 
Carboplatin + 
Placebo  
ALL Grades 
PXD + 
Carboplatin 
 > Grade 3 
Carboplatin 
+ Placebo 
> Grade 3 
PXD + 
Carboplatin           
Blood and lymphatic system disorders                            17 (24%)         14 ( 15.1%)         8 (  11.3%)        10 (15.1%)        
   Anaemia                                                      3 (4.2%)         1 (  1.5%)          0 (  0.0%)      0 (  0.0%)      
   Leukopenia                                                   2 (2.8%)         2 (  3.0%)       0 (  0.0%)      0 (  0.0%)      
   Neutropenia                                                   9 (12.7%)      6 (  9.1%)       6 (  8.5%)         6 (  9.1%) 
   Pancytopenia 1 (  1.4%)         0 (  0.0%)       0 (  0.0%)      0 (  0.0%)      
   Thrombocytopenia                                             8 (11.2%)         10 ( 15.1%)         2 (  2.8%)      6 (  9.1%)         
Gastrointestinal disorders                                      4 (5.6%)         9 ( 13.6%)          2 (  2.8%)      4 (  6.1%)         
   Abdominal pain                                               2 ( 2.8%)         1 (  1.5%)          1 (  1.4%)      0 (  0.0%)      
   Diarrhoea                                                    0 ( 0.0%)      5 ( 7.6%)          0 (  0.0%)      1( 1.5%)         
   Nausea                                                       1 ( 1.4%)         2 ( 3.0%)          1 (  1.4%)      0 (  0.0%)      
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                   Maximum CTC Grading 
 ALL Grades 
Carboplatin + 
Placebo  
ALL Grades 
PXD + 
Carboplatin 
 > Grade 3 
Carboplatin 
+ Placebo 
> Grade 3 
PXD + 
Carboplatin           
   Vomiting                                                     1 ( 1.4%)         3 (  4.5%)       1 (  1.4%)      2 (  3.0%)         
   Dysgeusia                                     0 (  0.0%)      1 (  1.5%)          0 (  0.0%)      0 (  0.0%)      
   Lethargy 1 (  1.5%)         0 (  0.0%)       0 (  0.0%)      0 (  0.0%)      
   Dyspnoea                                       1 (  1.4%)         0 (  0.0%)       0 (  0.0%)      0 (  0.0%)      
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Figure Legends 
Figure 1: CONSORT diagram: 
Figure 2: Kaplan-Meier curves for progression free survival in patients with platinum 
resistant ovarian cancer relapse treated with either carboplatin alone or carboplatin plus 
phenoxodiol. 
Figure 3: Kaplan-Meier curves for overall survival in patients with platinum resistant 
ovarian cancer relapse treated with either carboplatin alone or carboplatin plus 
phenoxodiol. 
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Entered Cycle 1 n=66 
Ceased treatment n=7 
Enter cycle 2 n=59 
Ceased treatment n=23 
No study drug n=4 
 
Enter cycle 3 n=36 
Ceased treatment n=9 
Enter cycle 4 n=27 
Ceased treatment n=10 
Enter cycle 5 n=17 
PXD + carbo n=70 
No study drug n=1 
 
Placebo + carbo n=72 
Ceased treatment n=2 
Enter cycle 6 n=15 
Ceased treatment n=6 
Enter cycle 7 n=9 
Ceased treatment n=2 
Enter cycle 8 n=7 
Ceased treatment n=4 
Enter cycle 9 n=3 
Ceased treatment n=0 
Enter cycle 10 n=3 
Ceased treatment n=1 
Enter cycle 11 n=2 
Enter cycle 12-15 n=1 
Entered Cycle 1 n=71 
Ceased treatment n=13 
Enter cycle 2 n=58 
Ceased treatment n=23 
Enter cycle 3 n=35 
Ceased treatment n=7 
Enter cycle 4 n=26 
Ceased treatment n=9 
Enter cycle 5 n=17 
Ceased treatment n=2 
Enter cycle 6 n=15 
Ceased treatment n=4 
Enter cycle 7 n=11 
Ceased treatment n=1 
Enter cycle 8 n=10 
Ceased treatment n=3 
Enter cycle 9 n=7 
Ceased treatment n=2 
Enter cycle 10 n=5 
Ceased treatment n=2 
Enter cycle 11-12 n=3 
Enter cycle 13 n=1 
Randomized n=142 
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Figure 2 
 
 
 
 
 
PXD + Carboplatin            Placebo + Carboplatin                                   
                                                                          (N=70)                             (N=72)                                           
_______________________________________   
_________________________________________________ 
Number of Patients Who Progressed                                     34 ( 48.6%)                     33 ( 45.8%)                                        
Number of Patients Who Died with No Prior Progression        23 ( 32.9%)                     20 ( 27.8%)                                        
Number of Patients Who Were Censored                                  13 ( 18.6%)                     19 ( 26.4%) 
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Figure 3: Kaplan-Meier curves for overall survival in patients with platinum resistant 
ovarian cancer relapse treated with either carboplatin alone or carboplatin plus 
phenoxodiol. 
 
 
 
 
 
PXD + Carboplatin            Placebo + Carboplatin                                   
                                                                          (N=70)                               (N=72)                                           
______________________________________________________________________________________
____ 
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Number of Patients Who Died                                           59 ( 84.3%)                    59 ( 81.9%)                                        
Number of Patients Who Were Censored                              11 ( 15.7%)                    13 ( 18.1%)                                        
______________________________________________________________________________________
_____                                                                                                                                                       
 
 
 
 
 
 
